These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26455272)

  • 1. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.
    Nolli C; Goffrini P; Lazzaretti M; Zanna C; Vitale R; Lodi T; Baruffini E
    Mitochondrion; 2015 Nov; 25():38-48. PubMed ID: 26455272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.
    Del Dotto V; Fogazza M; Musiani F; Maresca A; Aleo SJ; Caporali L; La Morgia C; Nolli C; Lodi T; Goffrini P; Chan D; Carelli V; Rugolo M; Baruffini E; Zanna C
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3496-3514. PubMed ID: 30293569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dynamics and disease, OPA1.
    Olichon A; Guillou E; Delettre C; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Daloyau M; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
    Biochim Biophys Acta; 2006; 1763(5-6):500-9. PubMed ID: 16737747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural model of the OPA1 GTPase domain may explain the molecular consequences of a novel mutation in a family with autosomal dominant optic atrophy.
    Dadgar S; Hagens O; Dadgar SR; Haghighi EN; Schimpf S; Wissinger B; Garshasbi M
    Exp Eye Res; 2006 Sep; 83(3):702-6. PubMed ID: 16698014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease.
    Delettre C; Lenaers G; Pelloquin L; Belenguer P; Hamel CP
    Mol Genet Metab; 2002 Feb; 75(2):97-107. PubMed ID: 11855928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPA1 haploinsufficiency induces a BNIP3-dependent decrease in mitophagy in neurons: relevance to Dominant Optic Atrophy.
    Moulis MF; Millet AM; Daloyau M; Miquel MC; Ronsin B; Wissinger B; Arnauné-Pelloquin L; Belenguer P
    J Neurochem; 2017 Feb; 140(3):485-494. PubMed ID: 27861891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy.
    Baris O; Delettre C; Amati-Bonneau P; Surget MO; Charlin JF; Catier A; Derieux L; Guyomard JL; Dollfus H; Jonveaux P; Ayuso C; Maumenee I; Lorenz B; Mohammed S; Tourmen Y; Bonneau D; Malthièry Y; Hamel C; Reynier P
    Hum Mutat; 2003 Jun; 21(6):656. PubMed ID: 14961560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation survey of the optic atrophy 1 gene in 193 Chinese families with suspected hereditary optic neuropathy.
    Chen Y; Jia X; Wang P; Xiao X; Li S; Guo X; Zhang Q
    Mol Vis; 2013; 19():292-302. PubMed ID: 23401657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies.
    Yu-Wai-Man P; Shankar SP; Biousse V; Miller NR; Bean LJ; Coffee B; Hegde M; Newman NJ
    Ophthalmology; 2011 Mar; 118(3):558-63. PubMed ID: 21036400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy.
    Thiselton DL; Alexander C; Taanman JW; Brooks S; Rosenberg T; Eiberg H; Andreasson S; Van Regemorter N; Munier FL; Moore AT; Bhattacharya SS; Votruba M
    Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1715-24. PubMed ID: 12036970
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Nitta Y; Osaka J; Maki R; Hakeda-Suzuki S; Suzuki E; Ueki S; Suzuki T; Sugie A
    Elife; 2024 Aug; 12():. PubMed ID: 39177028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First cases of dominant optic atrophy in Saudi Arabia: report of two novel OPA1 mutations.
    Galvez-Ruiz A; Neuhaus C; Bergmann C; Bolz H
    J Neuroophthalmol; 2013 Dec; 33(4):349-53. PubMed ID: 24051421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mgm1p, a dynamin-related GTPase, is essential for fusion of the mitochondrial outer membrane.
    Sesaki H; Southard SM; Yaffe MP; Jensen RE
    Mol Biol Cell; 2003 Jun; 14(6):2342-56. PubMed ID: 12808034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy.
    Kane MS; Alban J; Desquiret-Dumas V; Gueguen N; Ishak L; Ferre M; Amati-Bonneau P; Procaccio V; Bonneau D; Lenaers G; Reynier P; Chevrollier A
    J Cell Mol Med; 2017 Oct; 21(10):2284-2297. PubMed ID: 28378518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size.
    Barboni P; Carbonelli M; Savini G; Foscarini B; Parisi V; Valentino ML; Carta A; De Negri A; Sadun F; Zeviani M; Sadun AA; Schimpf S; Wissinger B; Carelli V
    Ophthalmology; 2010 Aug; 117(8):1547-53. PubMed ID: 20417568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
    Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
    Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder.
    Abrams AJ; Hufnagel RB; Rebelo A; Zanna C; Patel N; Gonzalez MA; Campeanu IJ; Griffin LB; Groenewald S; Strickland AV; Tao F; Speziani F; Abreu L; Schüle R; Caporali L; La Morgia C; Maresca A; Liguori R; Lodi R; Ahmed ZM; Sund KL; Wang X; Krueger LA; Peng Y; Prada CE; Prows CA; Schorry EK; Antonellis A; Zimmerman HH; Abdul-Rahman OA; Yang Y; Downes SM; Prince J; Fontanesi F; Barrientos A; Németh AH; Carelli V; Huang T; Zuchner S; Dallman JE
    Nat Genet; 2015 Aug; 47(8):926-32. PubMed ID: 26168012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPA1: How much do we know to approach therapy?
    Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
    Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Impairment Mechanisms of Novel OPA1 Mutations Predicted by Molecular Modeling in Patients With Autosomal Dominant Optic Atrophy and Auditory Neuropathy Spectrum Disorder.
    Namba K; Mutai H; Takiguchi Y; Yagi H; Okuyama T; Oba S; Yamagishi R; Kaneko H; Shintani T; Kaga K; Matsunaga T
    Otol Neurotol; 2016 Apr; 37(4):394-402. PubMed ID: 26905822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations.
    Agier V; Oliviero P; Lainé J; L'Hermitte-Stead C; Girard S; Fillaut S; Jardel C; Bouillaud F; Bulteau AL; Lombès A
    Biochim Biophys Acta; 2012 Oct; 1822(10):1570-80. PubMed ID: 22800932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.